http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Infrared Spectra of Internal Modes in Gd2(MoO4)3 near the Ferroelectric Phase Transition Temperature
Akira Sakai,Ken Honma 한국물리학회 2007 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.51 No.2I
In order to investigate the phase transition mechanism of the improper ferroelectric Gd2(MoO4)3, we observed infrared spectra above and below the phase transition temperature with special attention to the internal modes of the MoO4 molecules. At room temperature, the crystal orientation of the single domain was determined by the angular dependence of the transmittance of the spectrum peak. At the phase transition temperature, the doubly degenerate E mode split into two modes. The degree of splitting increased with decreasing temperature. The results are compared with the results of MoO4 internal modes observed by using Raman scattering measurements.
Chemical Control of Mammalian Circadian Behavior through Dual Inhibition of Casein Kinase Iα and δ
Lee, Jae Wook,Hirota, Tsuyoshi,Ono, Daisuke,Honma, Sato,Honma, Ken-ichi,Park, Keunwan,Kay, Steve A. American Chemical Society 2019 Journal of medicinal chemistry Vol.62 No.4
<P>Circadian rhythms are controlled by transcriptional feedback loops of clock genes and proteins. The stability of clock proteins is regulated by post-translational modification, such as phosphorylation by kinases. In particular, casein kinase I (CKI) phosphorylates the PER protein to regulate proteasomal degradation and nuclear localization. Therefore, CKI inhibition can modulate mammalian circadian rhythms. In the present study, we have developed novel CKIα and CKIδ dual inhibitors by extensive structural modification of N9 and C2 position of longdaysin. We identified NCC007 that showed stronger period effects (0.32 μM for 5 h period lengthening) in a cell-based circadian assay. The following in vitro kinase assay showed that NCC007 inhibited CKIα and CKIδ with an IC<SUB>50</SUB> of 1.8 and 3.6 μM. We further demonstrated that NCC007 lengthened the period of mouse behavioral rhythms in vivo. Thus, NCC007 is a valuable tool compound to control circadian rhythms through CKI inhibition.</P> [FIG OMISSION]</BR>
Sasaki, Yusuke,Hamaguchi, Tetsuya,Yamada, Yasuhide,Takahashi, Naoki,Shoji, Hirokazu,Honma, Yoshitaka,Iwasa, Satoru,Okita, Natsuko,Takashima, Atsuo,Kato, Ken,Nagai, Yushi,Taniguchi, Hirokazu,Boku, Nari Asian Pacific Journal of Cancer Prevention 2016 Asian Pacific journal of cancer prevention Vol.17 No.2
Background: It is well known that peritoneal carcinomatosis (PC) from colorectal cancer (CRC) is associated with a poor prognosis. However, data on the prognostic significance of modern chemotherapy containing bevacizumab, cetuximab or panitumumab are not available. Materials and Methods: This retrospective review concerned 526 patients with metastatic CRC who were classified into two groups according to the presence or absence of PC, and were treated with systemic chemotherapy, with or without bevacizumab or anti-EGFR antibodies. The genetic background, in particular KRAS, BRAF, and PIK3CA gene mutations, and overall survival (OS) were compared between the two groups. Results: The median OS values were 23.3 and 29.1 months for PC and non-PC patients, respectively (hazard ratio [HR]=1.20; p=0.17). Among all patients, tumor location, number of metastatic sites and BRAF mutation status were significant prognostic factors, whereas the presence of PC was not. In the PC group, chemotherapy with bevacizumab resulted in a significantly longer OS than forchemotherapy without bevacizumab (HR=0.38, p<0.01), but this was not the case in the non-PC group (HR=0.80, p=0.10). Furthermore, the incidence of the BRAF V600E mutation was significantly higher in PC than in non-PC patients (27.7% versus 7.3%, p<0.01). BRAF mutations displayed a strong correlation with shorter OS in non-PC (HR=2.26), but not PC patients (HR=1.04). Conclusions: Systemic chemotherapy, especially when combined with bevacizumab, improved survival in patients with PC from CRC as well as non-PC patients. While BRAF mutation demonstrated a high frequency in PC patients, but it was not associated with prognosis.